Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity
This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.
This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.
Study results support development of therapeutics that are targeted and based on individual genetic variants and would generalize across patient-groups in AML.
Clinical trials and drug approvals in the past several years have dramatically improved bladder cancer treatment.
The FDA granted accelerated approval to avelumab for the treatment of patients 12 years and older with Merkel cell carcinoma.
Racial disparities in treatment and outcomes persist among patients diagnosed with NSCLC in spite of advances in curative therapies.
SBRT may be an effective strategy for elderly patients with unresectable lung cancer.
Definitive reirradiation of thoracic cancers with IMPT can provide durable local control with minimal toxicity and can extend survival.
Post-radiotherapy samples in 20 of 22 recurrences revealed that 15 of these patients (75%) had an increase in CTC counts.
In an analysis of metastatic lung cancer treated with thoracic radiotherapy and immunotherapy, 3 patients had severe toxicity.
Resistance to EGFR-targeted therapies may not be permanent; a single biopsy is insufficient for fully understanding the nature of therapy resistance.